Fundz

Crinetics Pharmaceuticals, Inc. reported raising $60 Million in an initial SEC Form D filing, from an offering of $65 Million

TAKEN PRIVATEFeb 23, 2018$60M of $65M raised

Amount Raised

$60 Million

$60 Million sold, per SEC Form D (first sale Feb 23, 2018)

Round Type

Venture

San DiegoBiotechnologyHealthcareHealth CareTherapeuticsPharmaceuticalBiopharma

Who else raised in Healthcare and Therapeutics around the same time

Companies in the same sectors as Crinetics Pharmaceuticals that raised within 45 days of this round, from Fundz verified event records.

Who to call at Crinetics Pharmaceuticals, and when

A new round usually means Crinetics Pharmaceuticals is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Crinetics Pharmaceuticals raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Crinetics Pharmaceuticals, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Crinetics Pharmaceuticals. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Crinetics Pharmaceuticals

Location

San Diego, California, United States

About

Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors. Paltusotine, an investigational, first-in-class, oral somatostatin receptor type 2 (SST2) agonist, is in Phase 3 clinical development for acromegaly and Phase 2 clinical development for carcinoid syndrome associated with neuroendocrine tumors. Crinetics has demonstrated pharmacologic proof-of-concept in a Phase 1 clinical study for CRN04894 a first-in-class, investigational, oral ACTH antagonist, that is currently in Phase 2 clinical studies for the treatment of Cushing’s disease and congenital adrenal hyperplasia. All of the Company’s drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts, including additional discovery programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves’ disease, thyroid eye disease, hyperinsulinism, diabetes and obesity.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Crinetics Pharmaceuticals raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Verified contacts8 people are listed at Crinetics Pharmaceuticals. We don't have their email yet.See plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for Crinetics Pharmaceuticals's next move

See what Strategic adds

Crinetics Pharmaceuticals raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.